金乌骨通胶囊治疗肾虚督寒型强直性脊柱炎临床观察

Clinical observation on treating ankylosing spondylitis of the Shenxu Duhan type with the Jinwu Gutong capsule

目的:观察金乌骨通胶囊治疗强直性脊柱炎(Ankylosing Spondylitis,AS)肾虚督寒型的临床疗效及不良反应。方法:采取随机双盲方法。治疗组30例采用金乌骨通胶囊治疗;对照组30例采用柳氮磺吡啶片治疗。结果:治疗组可明显改善强直性脊柱炎肾虚督寒型患者的临床及实验室指标,如晨僵时间、扩胸试验、枕墙距、Schober试验、指地距、红细胞沉降率(Erythrocyte Sedimentation Rate,ESR)、C反应蛋白(C-reactive Protein,CRP)等,与治疗前比较,差异有统计学意义(P<0.05)。治疗后晨僵时间、Schober试验、指地距、ESR、CRP等指标与对照组比较,差异无统计学意义(P>0.05)。治疗组总有效率为83.33%,对照组总有效率为86.66%,两组比较无显著差异(P>0.05)。结论:金乌骨通胶囊治疗肾虚督寒型AS与柳氮磺吡啶(Salazosulfapyridine,SASP)疗效相当,无明显不良反应,适合该型患者临床使用。

Objective:To observe the clinical efficacy of the Jinwu Gutong capsule(金乌骨通胶囊)on ankylosing spondylitis of the Shenxu Duhan type(肾虚督寒型)and adverse reactions.Methods:Random double blind method was adopted.The treatment group(30 cases)was treated with the Jinwu Gutong capsule,while the control group(30 cases)was treated with sulfasalazine tablets.Results:In the treatment group,the clinical and laboratory indicators were more improved than before treatment,such as morning stiffness time,chest enlargement test,pillow wall distance,Schober test,finger-to-ground distance,ESR,CRP,etc.(P<0.05).There was no significant difference in morning stiffness time,Schober test,finger-to-ground distance,ESR and CRP between the two groups after treatment(P>0.05).The total efficiency was 83.33%in the treatment group and 86.66%in the control group.There was no significant difference between the two groups(P>0.05).Conclusion:The Jinwu Gutong capsule on AS showed same effects of SASP,with no obvious adverse reactions,is suitable for the clinical application in treating this type of AS.